Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000665852 | SCV000790039 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2017-03-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001053757 | SCV001218034 | pathogenic | Qualitative or quantitative defects of dysferlin | 2024-02-18 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Met459Asnfs*15) in the DYSF gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DYSF are known to be pathogenic (PMID: 17698709, 20301480). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with dysferlinopathy (PMID: 25591676, 27647186, 29797799, 30107846). This variant is also known as c.1370dupA. ClinVar contains an entry for this variant (Variation ID: 550946). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003465444 | SCV004194242 | pathogenic | Miyoshi muscular dystrophy 1 | 2023-11-22 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000665852 | SCV001458642 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2020-09-16 | no assertion criteria provided | clinical testing |